- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01243450
Bioequivalence Study of Generic Tretinoin 0.04% Microsphere Gel, 0.04% Retin-A Micro® and Placebo
December 28, 2019 updated by: Spear Pharmaceuticals
The objective will be to assess clinical bioequivalence of 0.1% Retin-A Micro® Gel and Spear Pharmaceutical's generic 0.1% Tretinoin Microsphere Gel with a placebo arm.
Study Overview
Detailed Description
Acne study
Study Type
Interventional
Enrollment (Actual)
958
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New Jersey
-
Mountain Lakes, New Jersey, United States, 07046
- Cu-Tech, LLC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
12 years to 40 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
A subject will be eligible to participate if they meet all of the following inclusion criteria:
- Normal, healthy male and female children and adults.
- Age 12 to 40 years.
- Written and verbal informed consent must be obtained. Subjects age 12 to 17 (inclusive) must sign an assent for the study and a parent or a legal guardian must sign the informed consent (per FDA letter 8.21.07).
- Women of child-bearing potential must be non-pregnant and non-nursing, and must be willing to avoid pregnancy during the course of the study and during the menstrual cycle following completion of their participation in the study, adequate contraception is defined as regular use of any two of the following: oral, injectable contraceptives, condoms, spermicides, diaphragm, IUD, implantable and contraceptive patches. (oral contraceptives if used for at least three months and injectable contraceptives if used for at least 6 months)- prior to enrollment in the study, or abstinence.
- Have at least 20 inflammatory (papules and pustules) and 25 non-inflammatory (open and closed comedones) lesions with a maximum of 2 nodulocystic lesions on the face (per FDA letter 8.21.07).
- Global severity score from 2-4
- Able to refrain from the use of all other topical acne medications or antibiotics during the treatment period.
- Considered reliable and capable of understanding their responsibility and role in the study.
Exclusion Criteria
A subject will be eligible to participate if they meet none of the following exclusion criteria:
- Subjects with active cystic acne as evidenced by more than 2 facial nodules.
- More than 40 papules and/or pustules (inflammatory lesions)
- More than 60 open and or closed comedones/milia (non-inflammatory lesions)
- Overall severity grade of less than 2 or greater than 4,
- History of allergy or hypersensitivity to tretinoin.
- Significant history or clinical evidence of auto-immune, cardiovascular, gastrointestinal, hematological, hepatic, neurological, pancreatic, or renal disease
- Use of systemic retinoid treatment within six months prior to study initiation.
- Oral contraceptives should not be started or changed within 3 months prior to study initiation or planned to change during the study.
- Pregnant or breast-feeding.
- Participation in a clinical study for acne within 4 months preceding study initiation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Active generic
Treatment of acne for 12 weeks with generic tretinoin
|
Treatment of acne
Other Names:
|
Placebo Comparator: Placebo
Treatment of acne for 12 weeks with Placebo
|
treatment of acne
Other Names:
|
Active Comparator: Brand
Treatment of acne over 12 weeks with tretinoin Brand
|
Treatment of acne
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acne Lesion Percent Reduction
Time Frame: 12 week
|
Reduction in number of Acne lesions by counting over 12 weeks
|
12 week
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: William Cunningham, MD, Cu-Tech
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2009
Primary Completion (Actual)
October 1, 2010
Study Completion (Actual)
October 1, 2010
Study Registration Dates
First Submitted
November 16, 2010
First Submitted That Met QC Criteria
November 17, 2010
First Posted (Estimate)
November 18, 2010
Study Record Updates
Last Update Posted (Actual)
January 3, 2020
Last Update Submitted That Met QC Criteria
December 28, 2019
Last Verified
November 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RAM-04
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acne
-
ProgenaBiomeRecruitingAcne Vulgaris | Acne | Acne Rosacea | Acne Inversa | Acne Keloidalis | Acne Keloid | Acne Conglobata | Acne Cystic | Acne Pomade | Acne Indurata | Acne Papular | Acne Tropica | Acne Urticata | Acne Fulminans | Acne Follicular | Acne Tropicalis | Acne Detergicans | Acne Iodide | Acne VarioliformisUnited States
-
Technische Universität DresdenUnknown
-
Chulalongkorn UniversityCompletedPost - Adolescence AcneThailand
-
National Yang Ming UniversityTaipei City HospitalUnknown
-
Elorac, Inc.Completed
-
Ulthera, IncCompleted
-
Novartis PharmaceuticalsCompletedInflammatory AcneGermany, United States, Hungary, France, Czechia, Netherlands
-
DarierUnknown
-
Seoul National University HospitalCompletedAcne, Photodynamic TherapyKorea, Republic of
-
Cipher Pharmaceuticals Inc.CompletedSevere Nodular AcneUnited States, Canada
Clinical Trials on Tretinoin
-
Northwestern UniversityNational Cancer Institute (NCI)Completed
-
University of Michigan Rogel Cancer CenterNational Cancer Institute (NCI)CompletedCervical Cancer | Precancerous/Nonmalignant ConditionUnited States
-
Dr.dr.Irma Bernadette, SpKK (K)Not yet recruiting
-
Srinakharinwirot UniversityRecruitingHyperpigmentation | Acanthosis NigricansThailand
-
Merete HaedersdalCompletedStriae DistensaeDenmark
-
Taro Pharmaceuticals USACompletedA Study Comparing Tretinoin Cream 0.025% and RETIN-A® Cream 0.025% in the Treatment of Acne VulgarisAcne VulgarisUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Withdrawn
-
University of UtahNot yet recruitingMetastatic Colon Cancer | Metastatic Rectum CancerUnited States
-
Taro Pharmaceuticals USACompleted
-
University of California, IrvineBeckman Laser Institute University of California Irvine; Unilever R&DCompletedCollagen Fibril AlterationUnited States